Renovaro Inc. financial data

Symbol
RENB on Nasdaq
Industry
Pharmaceutical Preparations
Location
Century City Medical Plaza, 2080 Century City East, Suite 906 Los Angeles, CA
State of incorporation
DE
Fiscal year end
June 30
Former names
RENOVARO BIOSCIENCES INC. (to 2/7/2024), Enochian Biosciences Inc (to 8/1/2023), DanDrit Biotech USA, Inc. (to 2/23/2018), Putnam Hills Corp. (to 2/11/2014)
Latest financial report
10-Q/A - Q1 2024 - Aug 20, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 14.5 % -80.3%
Debt-to-equity 29.8 % +61.8%
Return On Equity -130 % +16%
Return On Assets -100 % +23.4%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 148M shares +165%
Common Stock, Shares, Outstanding 147M shares +154%
Entity Public Float 45.4M USD -81.3%
Common Stock, Value, Issued 14.8K USD +154%
Weighted Average Number of Shares Outstanding, Basic 107M shares +92%
Weighted Average Number of Shares Outstanding, Diluted 107M shares +92%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 3.27M USD -33.8%
General and Administrative Expense 22.5M USD +45%
Operating Income (Loss) -87.5M USD +23.2%
Nonoperating Income (Expense) -647K USD -109%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -9.18M USD -19.2%
Net Income (Loss) Attributable to Parent -88.1M USD +17.4%
Earnings Per Share, Basic -1.1 USD/shares -500%
Earnings Per Share, Diluted -1.1 USD/shares -500%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 313K USD -89.4%
Cash, Cash Equivalents, and Short-term Investments 91.4K USD -97.6%
Assets, Current 1.22M USD -68.9%
Property, Plant and Equipment, Net 489K USD -7.62%
Operating Lease, Right-of-Use Asset 1.39M USD +43.8%
Intangible Assets, Net (Excluding Goodwill) 0 USD
Goodwill 164M USD +1311%
Other Assets, Noncurrent 176M USD +137%
Assets 178M USD +126%
Accrued Liabilities, Current 3.75M USD +532%
Liabilities, Current 20.9M USD +77.3%
Operating Lease, Liability, Noncurrent 970K USD +17%
Other Liabilities, Noncurrent 185K USD +10.9%
Liabilities 43.7M USD +247%
Accumulated Other Comprehensive Income (Loss), Net of Tax 1.03M USD
Retained Earnings (Accumulated Deficit) -309M USD -39.9%
Stockholders' Equity Attributable to Parent 134M USD +103%
Liabilities and Equity 178M USD +126%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -2.78M USD -4.66%
Net Cash Provided by (Used in) Financing Activities 2.56M USD +75.7%
Net Cash Provided by (Used in) Investing Activities -1.06M USD
Common Stock, Shares Authorized 350M shares +250%
Common Stock, Shares, Issued 147M shares +154%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.35M USD -12.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 313K USD -89.4%
Interest Paid, Excluding Capitalized Interest, Operating Activities 5.26K USD -82.7%
Deferred Tax Assets, Valuation Allowance 145M USD +94.7%
Depreciation 110K USD +3.68%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -87.1M USD +18.4%
Lessee, Operating Lease, Liability, to be Paid 1.45M USD
Property, Plant and Equipment, Gross 1.04M USD +7.16%
Operating Lease, Liability, Current 483K USD +134%
Lessee, Operating Lease, Liability, to be Paid, Year Two 558K USD
Lessee, Operating Lease, Liability, to be Paid, Year One 286K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure +24.8%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 109K USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 349K USD
Deferred Tax Assets, Operating Loss Carryforwards 141M USD +97.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 309K USD
Operating Lease, Payments 108K USD +9.59%
Additional Paid in Capital 442M USD +54.1%
Preferred Stock, Shares Outstanding 0 shares
Operating Leases, Future Minimum Payments, Due in Two Years 246K USD -17.5%
Amortization of Intangible Assets 9.13K USD +12.7%
Depreciation, Depletion and Amortization 119K USD +4.32%
Operating Leases, Future Minimum Payments Due, Next Twelve Months 60K USD -31.6%
Share-based Payment Arrangement, Expense 465K USD -43.2%
Operating Leases, Future Minimum Payments, Due in Three Years 253K USD +3%
Operating Leases, Future Minimum Payments Due 1.04M USD -21.2%
Interest Expense 304K USD +148%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%